한미사이언스

008930KOSPI

64.2 / 100

Reference Date: 2026-09-08

Financial Score19.0 / 40

News Sentiment19.2 / 25

Momentum16.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Surged 21.4% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Hanmi Science operates as a business holding company, generating revenue through equity income from subsidiaries, patent and trademark licensing fees, and healthcare and pharmaceutical wholesale businesses. The company focuses on innovation across medical devices, food, beauty care, and IT solutions, and expanded its portfolio through the 2022 acquisition of Hanmi Healthcare.

Number of Employees

489people

Average Salary

72.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

31.49Industry Average 15.000.0Point

2.1x industry avg (risky)

PBR

3.86Industry Average 1.200.0Point

3.2x industry avg (risky)

ROE

13.09Industry Average 8.005.5Point

1.6x industry avg (good)

Debt Ratio

4.83Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲4.3% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲9.9% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 11.8% (declining, 3yr)

Detailed News Sentiment

39 totalPositive 26Neutral 4Negative 9Average Sentiment Score 76.8

Positive
"QA 업무에 AI 도입"?한미약품, 'AX 원스톱 바우처 지원사업' ...
한미약품의 AI 기반 QA 시스템 도입으로 효율성 향상 및 품질 관리 강화 기대.
Positive
한미약품, AI로 공장 품질관리…정부 지원금 10억원 투입
한미약품이 AI 도입으로 품질관리 효율성 향상 기대, 기술 투자로 경쟁력 강화.
Positive
한미약품, 4000종 품질문서 AI로 학습…문서업무 자동화
한미약품이 AI 기술 도입으로 문서 처리 자동화를 통해 효율성 향상 기대.

Detailed Momentum

52-week position8.0Point

Near 52w high (92%, uptrend)

Current 54,200Won52-week high 56,50052-week low 26,100

1-month return6.0Point

1m +21.39% (strong rise)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

29 totalPositive 0Neutral 29Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-01
Neutral최대주주등소유주식변동신고서2026-09-01
Neutral주식등의대량보유상황보고서(일반)2026-09-01
Neutral[기재정정]투자판단관련주요경영사항(자회사의 주요경영사항) (급성골수성백혈병(AML) 치료 항암신약 HM43239 기술이전 계약 체결)2026-08-26
Neutral투자판단관련주요경영사항(자회사의 주요경영사항)2026-08-24